Table 2.
Characteristics of first-line immunotherapy.
| Characteristics | No. of patients (%) |
|---|---|
| PD-L1 expression | |
| <1%/undetected | 13 (61.9) |
| 1–49% | 2 (9.5) |
| ≥50% | 6 (28.6) |
| Immunotherapy strategies | |
| Monotherapy | 3 (14.3) |
| Immune+ anlotinib | 14 (66.7) |
| Chemoimmunotherapy | 4 (19.0) |
| Type of immunotherapy | |
| Tislelizumab | 7 (33.3) |
| Camrelizumab | 6 (28.6) |
| Sintilimab | 4 (19.0) |
| Pembrolizumab | 3 (14.3) |
| Durvalumab | 1 (4.8) |
| Best response | |
| PR | 12 (57.2) |
| SD | 5 (23.8) |
| PD | 4 (19.0) |
| Adverse events | |
| No | 16 (76.2) |
| Yes | 5 (23.8) |
ECOG, Eastern Cooperative Oncology Group; PR, partial response; SD, stable disease; PD, progressive disease.